Chronic Hepatitis B Relapse Rates after Cessation of Tenofovir Alafenamide and Entecavir Therapy

Chronic hepatitis B (CHB) relapse occurs after the cessation of nucleos(t)ide analogues (NUC) therapy due to the waning of viral suppression. Few studies have investigated the viral relapse rate and clinical relapse rate after tenofovir alafenamide (TAF) therapy. We compared the CHB relapse rate bet...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Chih-Wen, Yang, Chen-Ta, Su, Pei-Yuan, Chen, Yang-Yuan, Huang, Siou-Ping, Yen, Hsu-Heng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045269/
https://www.ncbi.nlm.nih.gov/pubmed/36979731
http://dx.doi.org/10.3390/biomedicines11030752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045269/
https://www.ncbi.nlm.nih.gov/pubmed/36979731
http://dx.doi.org/10.3390/biomedicines11030752

Ejemplares similares